Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics
Antibody Therapeutics · 29.06.2026 · 9 (3) · 273-292
DOI: 10.1093/abt/tbag022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 29.04.2026. Verfasst von Chen-Hsu Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, U…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CPRIT cancer therapeutics and training program, Welch Foundation, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
RNA-targeting therapeutics have enormous potential to precisely target disease-causing RNAs, extending beyond the traditional limits of “druggability” for small molecules, antibodies, and protein-targeting cell therapies. However, one crucial limitation is that RNA-targeting drug modalities (such as oligonucleotides) cannot effectively reach diseased tissue or cell types. Antibody-oligonucleotide conjugates (AOCs) emerge as a promising frontier in aiding RNA therapeutics by harnessing antibodies to deliver drug modalities to target specific RNAs in desired tissues or cells. In this Review, we summarize the critical components of AOCs, key considerations for their design and manufacturing, ongoing AOCs in preclinical/clinical development, and disease indications. We discuss the current hurdles to improving AOC efficacy and extending its application, concluding with an outlook on the unique opportunities offered by AOCs beyond traditional oligonucleotides and small-molecule antibody-drug conjugates. We propose that, with focused efforts to overcome key challenges, AOCs have the potential to transform RNA therapeutics, offering treatment options for many previously untreatable diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, United States.
- Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States.
ORCID-Profile: Chen-Hsu Yu, Summer Y Y Ha, Zhiqiang An, Kyoji Tsuchikama, Wenbo Li
Förderung
- CPRIT cancer therapeutics and training program
- Welch Foundation
- Cancer Prevention and Research Institute of Texas
- NIH
Zitieren
APA
Yu, C. H., Ha, S. Y. Y., An, Z., Tsuchikama, K., & Li, W. (2026). Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics. Antibody Therapeutics, 9(3), 273-292. https://doi.org/10.1093/abt/tbag022
Vancouver
Yu CH, Ha SYY, An Z, Tsuchikama K, Li W. Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics. Antibody Therapeutics. 2026;9(3):273-292. doi:10.1093/abt/tbag022
BibTeX
@article{Yu2026,
author = {Yu, Chen-Hsu and Ha, Summer Y Y and An, Zhiqiang and Tsuchikama, Kyoji and Li, Wenbo},
title = {Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {3},
pages = {273--292},
doi = {10.1093/abt/tbag022}
}
EUVIMED